Predictive Parameters After Molecular Absorbent Recirculating System Treatment Integrated With Model for End Stage Liver Disease Model in Patients With Acute-on-Chronic Liver Failure

Transplantation Proceedings

Volumn 42, Issue 4, 2010, Pages 1182-1187

  Novelli, G ^a   Rossi, M ^a   Ferretti, G ^a   Pugliese, F ^a   Travaglia, D ^a   Guidi, S ^a   Novelli, S ^a   Lai, Q ^a   Morabito, V ^a   Berloco, P B ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BILIRUBIN; CREATININE; DIURETIC AGENT; INTERLEUKIN 6; INTERLEUKIN 8; TUMOR NECROSIS FACTOR ALPHA;

ACUTE DISEASE; ADULT; ALBUMIN DIALYSIS; ALCOHOL LIVER CIRRHOSIS; ARTICLE; BACTERIAL INFECTION; CHRONIC DISEASE; CLINICAL ARTICLE; DEATH; DISEASE MODEL; DRUG USE; FEMALE; HEART INDEX; HOSPITAL ADMISSION; HUMAN; INTERNATIONAL NORMALIZED RATIO; LIVER FAILURE; LIVER TRANSPLANTATION; MALE; POSTOPERATIVE PERIOD; PREDICTION; PRIORITY JOURNAL; PROPHYLAXIS; RECEIVER OPERATING CHARACTERISTIC; SCORING SYSTEM; SENSITIVITY AND SPECIFICITY; SURVIVAL RATE; SURVIVAL TIME; UNIVARIATE ANALYSIS;

ADSORPTION; ADULT; CHRONIC DISEASE; FEMALE; HUMANS; LIVER CIRCULATION; LIVER FAILURE; LIVER FAILURE, ACUTE; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; SURVIVAL RATE; SURVIVORS; WAITING LISTS;

EID: 77952574139     PISSN: 00411345     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.transproceed.2010.03.095     Document Type: Article

References (36)

1. Christensen E. Prognostic models including the Child-Pugh, MELD and Mayo risk scores-where are we and where should we go?. J Hepatol 41 (2004) 344
2. Durand F., and Valla D. Assessment of the prognosis of cirrhosis: Child-Pugh versus MELD. J Hepatol 42 Suppl (2005) S100
3. Malinchoc M., Kamath P.S., Gordon F.D., et al. A model to predict poor survival in patients undergoing transjugular intrahepatic portosystemic shunts. Hepatology 31 (2000) 864
4. Durand F., and Valla D. Assessment of the prognosis of cirrhosis: Child-Pugh versus MELD. J Hepatol 42 (2005) S100
5. Gotthardt D., Weiss K.H., Baumgärtner M., et al. Limitations of the MELD score in predicting mortality or need for removal from waiting list in patients awaiting liver transplantation. Gastroenterology 9 (2009) 72
6. Cholongitas E., Marelli L., Kerry A., et al. Different methods of creatinine measurement significantly affect MELD scores. Liver Transpl 13 (2007) 523
7. Robert A., and Chazouille O. Prothrombin time in liver failure: time, ratio, activity percentage, or international normalized ratio?. Hepatology 24 (1996) 1392
8. O'Grady J.G., Gimson A.E., O'Brien C., et al. Controlled trials of charcoal hemoperfusion and prognostic factors in fulminant hepatic failure. Gastroenterology 94 (1988) 1186
9. O'Grady J.G., Alexander G.J., Hayllar K., et al. Early indicators of prognosis in fulminant hepatic failure. Gastroenterology 97 (1989) 439
10. Bone R.C. immunologic dissonance: a continuing evolution in our understanding of the systemic inflammatory response syndrome (SIRS) and the multiple organ dysfunction syndrome (MODS). Ann Intern Med 125 (1996) 680
11. Jalan R., Schnurr K., Mookerjee R.P., et al. Alterations in the functional capacity of albumin in patients with decompensated cirrhosis is associated with increased mortality. Hepatology 50 (2009) 555
12. Reiner W. Splanchnic and systemic vasodilation: the experimental models'. J Clin Gastroenterol 41 (2007) S272
13. McClain C.J., Barve S., and Deaciuc I. Cytokines in alcoholic liver disease. Semin Liver Dis 19 (1999) 205
14. McCuskey R.S., Nishida J., Eguchi H., et al. Role of endotoxin in the hepatic inflammatory response to ethanol. J Gastroenterol Hepatol 10 (1995) S18
15. Świa̧tkowska-Stodulska R., Ba̧kowska A., and Drobińska-Jurowiecka A. Interleukin-8 in the blood serum of patients with alcoholic liver disease. Med Sci Monit 12 (2006) CR215
16. Liu Q. Role of cytokines in the pathophysiology of acute-on-chronic liver failure. Blood Purif 28 (2009) 331
17. Deviere J., Le Moine L., Goldman M., et al. Cytokines and alcoholic liver cirrhosis. In: Gerok W., Decker K., and Andus T. (Eds). Cytokines and the Liver (1995), Kluwer Academic Publishers, Lancaster, England 127
18. Magosso E., Ursino M., Coli L., et al. A modeling study of bilirubin kinetics during molecular adsorbent recirculating system session. Artif Organs 30 (2006) 285
19. Stange J., Ramlow W., Mitzner S., et al. Dialysis against a recycled albumin solution enables the removal of albumin-bound toxins. Artif Organs 17 (1993) 809
20. Stange J., Mitzner S., Ramlow W., et al. A new procedure for the removal of proteinbound drugs and toxins. ASAIO J 39 (1993) 621
21. Evenepoel P., Maes B., Wilmer A., et al. Detoxifying capacity and kinetics of the molecular adsorbent recycling system. Blood Purif 21 (2003) 244
22. Jalan R., Sen S., Steiner C., et al. Extracorporeal liver support with molecular adsorbent recirculating system in patients with severe acute alcoholic hepatitis. J Hepatol 38 (2003) 24
23. Klammt S., Stange J., Mitzner S.R., et al. Extracorporeal liver support by recirculating albumin dialysis: analysing the effect of the first clinically used generation of the MARSystem. Liver 22 Suppl 2 (2002) 30
24. Mitzner S.R., Stange J., Klammt S., et al. Extracorporeal detoxification using the molecular adsorbent recirculating system for critically ill patients with liver failure. J Am Soc Nephrol 12 (2001) S75
25. Annesini M.C., Piemonte V., and Turchetti L. Artificial liver optimization: analysis of albumin bound toxin adsorption. Chemical Engineering Transactions 11 (2007) 551
26. Novelli G., Annesini M.C., Morabito V., et al. Cytokines levels modifications. Molecular adsorbent recirculating system versus standard medical therapy. Transplant Proc 41 (2009) 1243
27. Novelli G., Rossi M., Ferretti G., et al. Predictive criteria for the outcome of patients with acute liver failure treated with the albumin dialysis molecular adsorbent recirculating system. Ther Apher Dial 13 (2009) 404
28. Novelli G., Rossi M., Pugliese F., et al. Molecular adsorbents recirculating system treatment in acute-on-chronic hepatitis patients on the transplant waiting list improves model for end-stage liver disease scores. Transplant Proc 39 (2007) 1864
29. Merion R.M., Wolfe R.A., Dykstra D.M., et al. Longitudinal assessment of mortality risk among candidates for liver transplantation. Liver Transpl 9 (2003) 12
30. Bambha K., Kim W.R., Kremers W.K., et al. Predicting survival among patients listed for liver transplantation: an assessment of serial MELD measurements. Am J Transplant 4 (2004) 1798
31. Huo T.-I., Wu J.-C., Lin H.-C., et al. Evaluation of the increase in model for end-stage liver disease (DMELD) score over time as a prognostic predictor in patients with advanced liver cirrhosis: risk factor analysis and comparison with initial MELD and Child-Turoctte-Pugh score. J Hepatol 42 (2005) 826
32. Crews F.T., Bechara R., Brown L.A., et al. Cytokines and alcohol. Alcohol Clin Exp Res 30 (2006) 720
33. Sheron N., Bird G., Koskinas J., et al. Circulating and tissue levels of the neutrophil chemotaxin interleukin-8 are elevated in severe acute alcoholic hepatitis. Hepatology 18 (1993) 41
34. Mookerjee R.P., Sen S., Davies N.A., et al. Tumour necrosis factor α is an important mediator of portal and systemic haemodynamic derangements in alcoholic hepatitis. Gut 52 (2003) 1182
35. Hill D.B., Devalaraja R., Joshi-Barve S., et al. Antioxidants attenuate nuclear factor-kappa B activation and tumor necrosis factor-alpha production in alcoholic hepatitis patient monocytes and rat Kupffer cells, in vitro. Clin Biochem 32 (1999) 563
36. McClain C.J., and Cohen D.A. Increased tumor necrosis factor production by monocytes in alcoholic hepatitis. Hepatology 9 (1989) 349